Business
Montgomery Cancer Center Purchases IB's Software
Montgomery Cancer Center Purchases IB's Software.
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n \n \n \n RNS Number : 3019E\n IQ-AI Limited\n 05 November 2020\n \n \n \n \n IQ-AI Ltd\n \n \n (\"IQ-AI\" or the \"Company\")\n \n \n Montgomery Cancer Center Purchases Imaging Biometrics' Software\n \n \n Imaging Biometrics®, LLC (\"IB\"), a subsidiary of IQ-AI Limited (LON:IQAI), is pleased to announce that the Montgomery Cancer Center (Montgomery, Alabama, USA), has purchased IB Clinic. The Montgomery Cancer Center, one of the largest freestanding centers in the USA, will now be able to automatically generate quantitative parameters using IB's standardised brain tumour imaging protocol for the benefit of patients. \n \n \n The installation of IB Clinic includes the IB Neuro™ and IB Delta T1 mapping algorithms. These two maps continue to gain acceptance in brain tumour imaging and assessment. Delta T1 maps offer an objective and rapid visual assist for neuro radiologists. Specifically, the unique maps clearly identify subtle regions of contrast enhancement on routine MR images while, at the same time, eliminate confounding factors such as post-surgical blood products and other artifacts. Then, after the enhancing region is identified on the Delta T1 maps, IB Neuro's blood volume maps are used to quantitatively answer what the Board considers is the most important question in neuro oncology today: Is the enhancing region showing tumour or is it an effect due to treatment? \n \n The Directors of the Company accept responsibility for the contents of this announcement.\n \n -ENDS-\n For further information, please contact:\n \n \n \n IQ-AI Limited\n Trevor Brown/Vinod Kaushal/Qu Li\n Tel: 020 7469 0930\n \n \n \n \n Peterhouse Capital Limited (Financial Adviser and Broker)\n Lucy Williams/Heena Karani\n Tel: 020 7220 9797\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communic...